Medivation (MDVN) is expected to release the results of its Phase 3 clinical trial of Dimebon in the not to distant future. Dimebon is designed for the treatment of Alzheimer's disease.....By Bob DeMarco
Pfizer Medivation previously announced the Dimebon CONNECTION study results would be released during the first half of 2010.
There is great expectation not only in the Alzheimer's community but amongst investors.
Alzheimer's disease effects more than 5 million people in the United States, and more than 30 million worldwide. These numbers are expected to triple by 2050.
